Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review Review

publication date

  • December 31, 2026

webpage

published in

keywords

  • CRSwNP
  • Depemokimab
  • IL-5
  • biologics
  • chronic rhinosinusitis with nasal polyposis
  • eosinophil
  • interleukin-5
  • mepolizumab
  • type 2 inflammation

volume

  • 22

issue

  • 1